Clinical Research Directory

Inclusion Criteria: * Subjects who received the investigational medicinal product in the Phase 1/2a clinical trial (ASB-IP-001). * Subjects who voluntarily agreed to participate in this long-term follow-up study and provided written informed consent. Exclusion Criteria: * Subjects who cannot be contacted by any means, including telephone, mail, or e-mail, and for whom follow-up assessment is therefore not feasible. * Subjects deemed inappropriate for participation in this long-term follow-up study at the investigator's discretion, including: * Cases in which participation in the study may pose a significant risk to the subject's health or safety; ② Cases in which long-term follow-up visits or assessments are practically impossible due to cognitive impairment, communication difficulties, or similar conditions; ③ Cases in which continued participation in follow-up is unlikely due to difficulty adhering to the study schedule (e.g., prolonged hospitalization, long-term residence abroad).